JNJ
Johnson & Johnson
NYSE
Healthcare
$243.46
+0.94
(+0.39%)
Updated: 3/31/2026, 4:00:01 PM
Open
$243.01
High
$245.28
Low
$242.63
Prev Close
$242.49
Volume
1.84M
Price History
Why Is JNJ ▲ Up Today?
+0.39%
Full AI analysis generates after market close. Showing live price data.
Mar 31
▲
+0.4%
JNJ edges higher amid positive sentiment in healthcare sector
Mar 30
▲
+0.3%
JNJ edges higher amid positive sector sentiment and new data
Mar 27
▲
+0.5%
JNJ Up Slightly After FDA Approves Psoriasis Pill
Mar 26
—
-0.0%
JNJ Slightly Down Amidst Mixed Sector Performance
Mar 25
▲
+2.0%
JNJ Up on FDA Approval of Psoriasis Pill, Sector Strength
Mar 24
—
-0.1%
JNJ dips slightly despite sector gains, new FDA approval
Mar 23
▼
-0.2%
JNJ dips slightly despite positive news, sector weakness
Mar 20
▼
-0.7%
JNJ dips slightly despite positive news, new FDA approval
Mar 19
▲
+0.1%
J&J edges higher amid sector weakness, psoriasis pill approval
Mar 18
▼
-0.5%
JNJ dips slightly amid sector weakness, despite positive catalysts
Mar 17
▼
-1.9%
JNJ Declines Amid Sector Weakness and Profit-Taking
Mar 16
▲
+0.8%
JNJ Rises Slightly Amid Positive Sector Sentiment
Mar 13
▼
-0.4%
JNJ Down Slightly Despite Positive News, Broader Sector Weakness
Mar 12
▼
-0.4%
JNJ edges down slightly amid sector weakness
Mar 11
▼
-0.3%
JNJ Down Slightly Amid Sector Rotation and Mixed News
Mar 10
▲
+0.5%
JNJ Up Slightly Amidst Mixed Sector Performance
Mar 9
▲
+0.9%
JNJ Rises on FDA Approval of Multiple Myeloma Combo
Mar 6
▼
-0.2%
JNJ dips slightly despite FDA approval and analyst optimism
Mar 5
▼
-2.3%
JNJ dips amid sector weakness and competition concerns
Mar 4
▼
-1.0%
JNJ dips slightly amid mixed signals, AbbVie competition
Mar 3
▼
-0.7%
JNJ dips slightly amid sector weakness, AbbVie competition
Mar 2
▼
-0.1%
JNJ dips slightly amid sector weakness, AbbVie competition
Feb 27
▲
+2.0%
JNJ up 2.04% as healthcare sector rallies
Feb 26
▼
-0.7%
JNJ Down Slightly Despite Positive Sector News
Feb 25
▼
-0.7%
JNJ Down Slightly Despite Positive Sector News, Dividend King Status
Feb 24
—
+0.1%
JNJ edges higher amid sector weakness, positive news
Feb 23
▲
+1.4%
J&J Rises on Potential Orthopedics Sale, Cancer Drug Breakthrough
Feb 20
▼
-2.0%
J&J Down Nearly 2% Amid Sector Weakness, DePuy Synthes Sale Rumors
Feb 19
▲
+0.7%
JNJ edges higher on FDA nod, potential orthopedics sale
Feb 18
▲
+0.3%
JNJ edges higher on cancer drug progress, Pennsylvania plant plan
Financial Highlights
Income Statement
Revenue
$92.15B
Gross Profit
$62.73B
68.1% margin
Operating Income
$31.50B
34.2% margin
Net Income
$25.12B
27.3% margin
EPS (Diluted)
$10.36
Balance Sheet
Total Assets
$192.82B
Total Liabilities
$113.54B
Stockholders' Equity
$79.28B
Cash Flow
Operating Cash Flow
$24.20B
Investing Activities
-$20.42B
Net Cash Flow
-$1.75B
Highly Regarded Analysis for JNJ
Get a deep-dive analysis including bull/bear cases, technical outlook, price targets, and key catalysts — powered by Highly Regarded's proprietary analysis engine.
Usually takes 10-20 seconds
Analyzing JNJ...
Searching financial data and generating insights
Analysis couldn't be generated
Key Stats
P/E Ratio
23.5x
EPS (Diluted)
$10.36
Gross Margin
68.1%
Operating Margin
34.2%
Net Margin
27.3%
Revenue (Qtr)
$92.15B
Shares Outstanding
2.41B
Next Earnings
Date
Jul 15, 2026
Time
Before Open
Quarter
Q2 2026
EPS Estimate
$2.85
JNJ News
No recent news for JNJ.